The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator
Authors:
- Jin-Ki KimJKJin-Ki Kim
- Jeong-Sook ParkJeong-Sook Park
- Youngro ByunYBYoungro Byun
- Chong-Kook KimCKChong-Kook Kim
- 1 October 2009
- journal article
- Published by Elsevier in Biomaterials
- Vol. 30 (29) , 5751-5756
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Polymeric protein delivery systemsProgress in Polymer Science, 2007
- Strategies to improve plasma half life time of peptide and protein drugsAmino Acids, 2006
- Plasminogen activators: A comparisonVascular Pharmacology, 2006
- Enhancement of polyethylene glycol (PEG)-modified cationic liposome-mediated gene deliveries: effects on serum stability and transfection efficiencyJournal of Pharmacy and Pharmacology, 2003
- Controlled release of clot-dissolving tissue-type plasminogen activator from a poly(l-glutamic acid) semi-interpenetrating polymer network hydrogelJournal of Controlled Release, 2001
- Trends and Developments in Liposome Drug Delivery SystemsJournal of Pharmaceutical Sciences, 2001
- Effect of grafted PEG-2000 on the size and permeability of vesiclesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1996
- Tissue-type plasminogen activator: Characteristics, applications and production technologyBiotechnology Advances, 1996
- Liposomes as carriers for polypeptidesAdvanced Drug Delivery Reviews, 1989
- Streptokinase, urokinase, and tissue plasminogen activator: Pharmacokinetics, relative advantages, and methods for maximizing rates and consistency of lysisCardioVascular and Interventional Radiology, 1986